Caveolin-1 News Research Articles

Featured Genetics Neurology Neuroscience

·May 26, 2026·10 min read

Gene Therapy Proven to Shield Brain from TDP-43 Damage

An experimental gene therapy called SynCav1 can protect the central nervous system from the cognitive decline linked to TDP-43-related proteinopathy, a primary driver of FTD, ALS, and over half of all Alzheimer’s cases.

Caveolin-1

Gene Therapy Proven to Shield Brain from TDP-43 Damage

Modified FDA Drug Blocks Pediatric Brain Tumor Relapse

Blood Proteins Identified That Predict Multiple Sclerosis Early

Gene Therapy Proven to Shield Brain from TDP-43 Damage

Estrogen Loss May Drive Female Alzheimer’s

Gene Therapy Proven to Shield Brain from TDP-43 Damage

Modified FDA Drug Blocks Pediatric Brain Tumor Relapse

Blood Proteins Identified That Predict Multiple Sclerosis Early

Gene Therapy Proven to Shield Brain from TDP-43 Damage

Estrogen Loss May Drive Female Alzheimer’s

Subscribe